Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.58 |
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325012 | 0.89 | RAB9A (0.55) | MAPTRAB9ANPC1TP53MEN1 | |
| SCHEMBL6323345 | 0.88 | RAB9A (0.50) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL6324529 | 0.88 | MAPT (0.52) | MAPTRAB9ANPC1TP53MEN1 | |
| SCHEMBL6326802 | 0.87 | MAPT (0.55) | MAPTRAB9ANPC1TP53MEN1 | |
| SCHEMBL6323159 | 0.87 | BLM (0.57) | MAPTRAB9AMEN1KMT2AHTT | |
| SCHEMBL6329453 | 0.87 | BLM (0.52) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL6323889 | 0.86 | SMN1; SMN2 (0.47) | MAPTRAB9ANPC1TP53MEN1 | |
| SCHEMBL6325807 | 0.86 | TRPV1 (0.51) | MAPTRAB9ANPC1TP53MEN1 | |
| SCHEMBL6325956 | 0.83 | BLM (0.53) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL6321561 | 0.83 | BLM (0.54) | MAPTRAB9ANPC1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | claimed |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | SERPINE1, SERPINC1, SERPINB1 | MAPT 3022/4885RAB9A 3129/4885NPC1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.